$VTRS Viatris buys Pacira BioSciences for $1.65 billion in cash.
By Nexqual Desk ·
Tickers: $VTRS
$VTRS Viatris buys Pacira BioSciences for $1.65 billion in cash.
• The deal values Pacira at $36.50 per share in an all-cash transaction.
• Adds non-opioid pain therapies EXPAREL and ZILRETTA to the Viatris portfolio.
• The acquisition is expected to close by the end of 2026.
Source: SEC 8-K, Oct 8, 2026.
2 likes
Posted on Nexqual Sonar — the social network for the stock market. Not financial advice.